XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 4, 2009, Pages 382-390

  Pinho, Marcos B ^a   Costas, Fernanda ^a   Sellos, João ^a   Dienstmann, Rodrigo ^a   Andrade, Patricia B ^b   Herchenhorn, Daniel ^a   Peixoto, Fábio Afonso ^a   Santos, Valdelice O ^a   Small, Isabele A ^a   Guimarães, Denise P ^a   Ferreira, Carlos G ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Eli Lilly do Brasil   (Brazil)

Author keywords

Bladder carcinoma; mRNA; Outcome; XAF1

Indexed keywords

CISPLATIN; GEMCITABINE; MESSENGER RNA; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ASSOCIATED FACTOR 1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DYING; FEMALE; GENE EXPRESSION; HUMAN; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 67649336583     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.03.016     Document Type: Article

References (48)

1. Takata R., Katagiri T., Kanehira M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11 (2005) 2625-2636
2. Instituto Nacional de Câncer and Ministério da Saúde Cancer no Brasil: Dados dos registros de câncer de base populacional. INCA, Rio de Janeiro (2006).
3. Baffa R., Letko J., McClung C., et al. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res 25 (2006) 145-160
4. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163 (2000) 112494 >9.
5. Gschwend J.E., Simon J., Volkmer B., et al. Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity. Urology 42 (2003) 1445-1449
6. von der M.H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study J Clin Oncol 18 (2000) 3068-3077
7. de Braud F., Maffezzini M., Vitale V., et al. Bladder cancer. Crit Rev Oncol Hematol 41 (2002) 89-106
8. Robert J., Vekris A., Pourquier P., et al. Predicting drug response based on gene expression. Crit Rev Oncol Hematol 51 (2004) 205-227
9. Makin G., and Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 11 (2001) S22-S26
10. Wright C.W., and Duckett C.S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 115 (2005) 2673-2678
11. Schimmer A.D., Dalili S., Batey R.A., et al. Targeting XIAP for the treatment of malignancy. Cell Death Differ 13 (2006) 179-188
12. Schimmer A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 64 (2004) 7183-7190
13. Devi G.R. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect 17 (2004) 127-134
14. Emamaullee J., Liston P., Korneluk R.G., et al. XIAP overexpression in islet β-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 5 (2005) 1297-1305
15. Ma T.L., Ni P.H., Zhong J., et al. Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis 6 (2005) 10-14
16. Creagh E.M., Murphy B.M., Duriez P.J., et al. Smac/DIABLO antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J Biol Chem 279 (2004) 26906-26914
17. Shiozaki E.N., and Shi Y. Caspases, IAPs, and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem Sci 29 (2004) 486-494
18. Althaus J., Siegelin M.D., Dehghani F., et al. The serine protease Omi/HtrA2 is involved in XIAP cleavage and in neuronal cell death following focal cerebral ischemia/reperfusion. Neurochem Int 50 (2007) 172-180
19. Trencia A., Fiory F., Maitan M.A., et al. Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15. J Biol Chem 279 (2004) 46566-46572
20. Hegde R., Srinivasula S.M., Datta P., et al. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem 278 (2003) 38699-38706
21. Deveraux Q.L., Takahashi R., Salvesen G.S., et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
22. Fong W.G., Liston P., Rajcan-Separovic E., et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 70 (2000) 113-122
23. Liston P., Fong W.G., Kelly N.L., et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 3 (2001) 128-133
24. Leaman D.W., Chawla-Sarkar M., Vyas K., et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 277 (2002) 28504-28511
25. Leaman D.W., Chawla-Sarkar M., Jacobs B., et al. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: Greater potency of IFN-β compared with IFN-α2. J Interferon Cytokine Res 23 (2003) 745-756
26. Wang J., Peng Y., Sun Y.W., et al. All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology 130 (2006) 747-758
27. Byun D.S., Cho K., Ryu B.K., et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63 (2003) 7068-7075
28. Fang X., Liu Z., Fan Y., et al. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer 118 (2006) 2485-2489
29. Ng K.C., Campos E.I., Martinka M., et al. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 123 (2004) 1127-1134
30. Perrelet D., Perrin F.E., Liston P., et al. Motoneuron resistance to apoptotic cell death in vivo correlates with the ratio between X-linked inhibitor of apoptosis proteins (XIAPs) and its inhibitor, XIAP-associated factor 1. J Neurosci 24 (2004) 3777-3785
31. Herchenhorn D., Dienstmann R., Peixoto F.A., et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 5 (2007) 630-638
32. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
33. Kempkensteffen C., Hinz S., Schrader M., et al. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: Correlations with pathology and outcome. Cancer Lett 254 (2007) 227-235
34. Lee M.G., Huh J.S., Chung S.K., et al. Promoter CpG hypermethylation and down-regulation of XAF1 expression in human urogenital malignancies: Implication for attenuated p53 response to apoptotic stresses. Oncogene 25 (2006) 5807-5822
35. Qi R., Gu J., Zhang Z., et al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther 14 (2007) 82-90
36. Chen G.H., Lin F.R., Ren J.H., et al. Expression and significance of X-linked inhibitor of apoptosis protein and its antagonized proteins in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14 (2006) 639-643
37. Ng K.C., Campos E.I., Martinka M., et al. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 123 (2004) 1127-1134
38. Byun D.S., Cho K., Ryu B.K., et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63 (2003) 7068-7075
39. Byun D.S., Cho K., Ryu B.K., et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63 (2003) 7068-7075
40. Ishiguro M., Iida S., Uetake H., et al. Effect of combined therapy with low-dose 5-Aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14 (2006) 1752-1762
41. Jang J.Y., Kim H.J., Chi S.G., et al. Frequent epigenetic inactivation of XAF1 by promoter hypermethylation in human colon cancers. Korean J Gastroenterol 45 (2005) 285-293
42. Zou B., Chim C.S., Zeng H., et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 131 (2006) 1835-1843
43. Straszewski-Chavez S.L., Visintin I.P., Karassina N., et al. XAF1 mediates TNF-α-induced apoptosis and XIAP cleavage by acting through the mitochondrial pathway. J Biol Chem 282 (2007) 13059-13072
44. Cullen K.J., Yang Z., Schumaker L., et al. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39 (2007) 43-50
45. Yang Z., Schumaker L.M., Egorin M.J., et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res 12 (2006) 5817-5825
46. Christgen M., Schniewind B., Jueschke A., et al. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett 227 (2005) 193-200
47. Ferreira C.G., van der Valk P., Span S.W., et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 7 (2001) 2468-2474
48. Liu S.S., Tsang B.K., Cheung A.N., et al. Antiapoptotic proteins, apoptotic and proliferative parameters, and their prognostic significance in cervical carcinoma. Eur J Cancer 37 (2001) 1104-1110